Ion-pair formation combined with a penetration enhancer as a dual strategy to improve the transdermal delivery of meloxicam
Tóm tắt
The aim of the study was to develop a novel drug-in-adhesive patch for transdermal delivery of meloxicam (MLX). The formulation involved a strategy to combine a chemical enhancer with an ion-pair agent. Diethylamine (DETA) was selected as the counter ion to form the ion-pair agent MLX-DETA. MLX-DETA was characterized by nuclear magnetic resonance spectroscopy (NMR) and Fourier transform infrared spectroscopy (FTIR). The ion-pair lifetime (T
life) of MLX-DETA was 164.1 μs. The water solubility of MLX-DETA was increased nearly 9.3-fold, compared with that of MLX. Oleic acid (OA) was selected as the chemical enhancer, and the optimized formulation consisted of 5% (w/w) MLX-DETA, 5% (w/w) oleic acid, and DURO-TAK® 87-4098 adhesive as the pressure-sensitive adhesive matrix. The permeation study in vitro showed that both the counter ion and chemical enhancer were effective in improving the skin permeation of MLX. Tissue distribution studies demonstrated that higher accumulation of MLX following application of the MLX-DETA patch to the skin could be obtained in rats compared with the MLX-patch group. In conclusion, to increase the skin absorption and obtain a sustained release for the transdermal delivery of MLX, preparation of a drug-in-adhesive patch by combining an ion pair (MLX-DETA) with a permeation enhancer (OA) is a suitable strategy.
Tài liệu tham khảo
Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol. 1996;35(Suppl 1):4–12.
Noble S, Balfour JA. Meloxicam. Drugs. 1996;51(3):424–30. discussion 431-432
Alomrani AH, Badran MM. Flexosomes for transdermal delivery of meloxicam: characterization and antiinflammatory activity. Artif Cells Nanomed Biotechnol. 2016;28:1–8.
Chang JS, Huang YB, Hou SS, Wang RJ, Wu PC, Tsai YH. Formulation optimization of meloxicam sodium gel using response surface methodology. Int J Pharm. 2007;338(1–2):48–54.
Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995;44(10):423–33.
Lipscomb GR, Wallis N, Armstrong G, Rees WD. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Clin Pharmacol. 1998;46(2):133–7.
Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22(4):400–10.
Yang M, Wang HT, Zhao M, et al. Network meta-analysis comparing relatively selective COX-2 inhibitors versus coxibs for the prevention of NSAID-induced gastrointestinal injury. Medicine. 2015;94(40):e1592.
Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol Suppl. 1996;102:29–37.
Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–81.
Xi H, Cun D, Xiang R, et al. Intra-articular drug delivery from an optimized topical patch containing teriflunomide and lornoxicam for rheumatoid arthritis treatment: does the topical patch really enhance a local treatment? J Control Release. 2013;169(1–2):73–81.
Chen J, Gao Y. Strategies for meloxicam delivery to and across the skin: a review. Drug Deliv. 2016;23(8):3146–56.
Zhang Y, Cun D, Kong X, Fang L. Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy. Asian J Pharm Sci. 2014;9(5):251–9.
Ah Y-C, Choi J-K, Choi Y-K, Ki H-M, Bae J-H. A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization. Int J Pharm. 2010;385(1–2):12–9.
Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–37.
Fang L, Numajiri S, Kobayashi D, Morimoto Y. The use of complexation with alkanolamines to facilitate skin permeation of mefenamic acid. Int J Pharm. 2003;262(1–2):13–22.
Jantharaprapap R, Stagni G. Effects of penetration enhancers on in vitro permeability of meloxicam gels. Int J Pharm. 2007;343(1–2):26–33.
Han HK, Choi HK. Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm. 2007;65(1):99–103.
Zhang JY, Fang L, Tan Z, Wu J, He ZG. Influence of ion-pairing and chemical enhancers on the transdermal delivery of meloxicam. Drug Dev Ind Pharm. 2009;35(6):663–70.
Simon JD, Peters KS. Picosecond dynamics of ion pairs: the effect of hydrogen bonding on ion-pair intermediates. J Am Chem Soc. 1982;104:5.
Xi H, Cun D, Wang Z, et al. Effect of the stability of hydrogen-bonded ion pairs with organic amines on transdermal penetration of teriflunomide. Int J Pharm. 2012;436(1–2):857–61.
OECD. OECD guideline for testing of chemicals—acute dermal irritation, corrosion, revised version, Guideline No. 404, adopted may 1981. Rome: OECD; 2002a.
Arunan E, Desiraju GR, Klein RA, et al. Defining the hydrogen bond: an account (IUPAC technical report). Pure Appl Chem. 2011;83(8):1619–36.
Biliskov N, Prodi BK, Gregor M, Molcanov K, Stare J. A partial proton transfer in hydrogen bond in crystals of anhydrous potassium and rubidium complex Chloranilates. J Phys Chem. 2011;115:3154–66.
Sing P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther. 1993;268(1):144–51.
Ongprpattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res. 1991;8:350–4.